Japanese and German Case Series in Corticobasal Degeneration
📖 Wiki Page
disease956 wordssynced 2026-04-02
Japanese and German Case Series in Corticobasal Degeneration
Overview
Japanese and German neuropathology traditions have produced highly influential case series on corticobasal degeneration (CBD), contributing critical insights into clinical presentation, disease progression, and diagnostic markers. These series represent some of the largest pathologically-confirmed cohorts worldwide.
Japanese Case Series
J-VAC Study Group
The Japanese Validation study of Autopsy-proven Corticobasal degeneration (J-VAC) has produced several landmark publications:
Clinical Course of Pathologically Confirmed CBD (PMID:38090279)
Median survival time: 7.0 years from symptom onset
50% of patients diagnosed as CBD/CBS at final presentation
Key clinical features: asymmetric rigidity, apraxia, cortical sensory loss
Retrospective analysis of 19 pathologically-confirmed CBD patients vs 16 mimics
Identified key imaging markers for differential diagnosis
Focused on cortical atrophy patterns and white matter changes
Clinical Characteristics of Japanese CBD Patients (PMID:39243604)
Explored phenotypic variations in Japanese population
Pathological investigations essential for definitive diagnosis
Published 2024
JALPAC Study Group
Japanese Longitudinal Biomarker Study (PMID:39534091)
Multicenter prospective registry study initiated in 2014
Clinical features analysis of Japanese PSP and CBD patients
Biomarker correlates including CSF and imaging markers
...
Japanese and German Case Series in Corticobasal Degeneration
Overview
Japanese and German neuropathology traditions have produced highly influential case series on corticobasal degeneration (CBD), contributing critical insights into clinical presentation, disease progression, and diagnostic markers. These series represent some of the largest pathologically-confirmed cohorts worldwide.
Japanese Case Series
J-VAC Study Group
The Japanese Validation study of Autopsy-proven Corticobasal degeneration (J-VAC) has produced several landmark publications:
Clinical Course of Pathologically Confirmed CBD (PMID:38090279)
Median survival time: 7.0 years from symptom onset
50% of patients diagnosed as CBD/CBS at final presentation
Key clinical features: asymmetric rigidity, apraxia, cortical sensory loss
Retrospective analysis of 19 pathologically-confirmed CBD patients vs 16 mimics
Identified key imaging markers for differential diagnosis
Focused on cortical atrophy patterns and white matter changes
Clinical Characteristics of Japanese CBD Patients (PMID:39243604)
Explored phenotypic variations in Japanese population
Pathological investigations essential for definitive diagnosis
Published 2024
JALPAC Study Group
Japanese Longitudinal Biomarker Study (PMID:39534091)
Multicenter prospective registry study initiated in 2014
Clinical features analysis of Japanese PSP and CBD patients
Biomarker correlates including CSF and imaging markers
Key Japanese Researchers
| Researcher | Institution | Key Contributions | |------------|-------------|-------------------| | Iwasaki Y | Nagasaki University | Pathological characterization | | Yoshida M | Kinoura University | Neuropathology of CBD | | Mizusawa H | Tokyo Medical and Dental University | Historical reviews | | Aiba I | National Hospital Organization | J-VAC lead | | Sone J | Kanazawa University | Clinical biomarkers |
German Case Series
GWAS and Genetic Studies
The German research group led by Günter Höglinger (Munich) has produced foundational genetic studies:
Demonstrates link between subcortical tau accumulation and cortical hypoperfusion
Important for understanding disease propagation mechanisms
Clinical Phenotype Differences
| Feature | Japanese Series | Western Series | |---------|-----------------|----------------| | Age at onset | ~60-65 years | ~60-70 years | | Disease duration | 7-8 years | 6-8 years | | Apraxia prevalence | 70-80% | 60-70% | | Cortical sensory loss | 40-50% | 30-40% |
Diagnostic Challenges
Both Japanese and German series emphasize:
Clinical-pathological correlation: CBS during life often does not correlate with CBD at autopsy
Phenotypic variability: Significant overlap with PSP, FTD, and DLB
Biomarker importance: MRI, PET, and CSF markers increasingly important for antemortem diagnosis
Therapeutic Implications
Findings from Japanese and German case series directly inform current therapeutic strategies:
Targeting 4R-Tau Pathology
Both Japanese and German neuropathology studies confirm the predominance of [4R-tau](/proteins/tau) filaments in CBD, sharing this feature with [PSP](/diseases/progressive-supranuclear-palsy). This genetic and pathological overlap suggests:
Common therapeutic targets: Anti-tau antibodies, tau aggregation inhibitors, and tau-targeted immunotherapy may benefit both CBD and PSP patients
MAPT genetic risk factor: The H1 haplotype identified in the German GWAS is shared with PSP, making [MAPT](/genes/mapt) a high-priority target
Early diagnosis importance: Japanese series demonstrate that earlier clinical recognition enables enrollment in disease-modifying trials before extensive neuronal loss
Ongoing Clinical Trials
The Höglinger group (Munich) coordinates several CBD-focused trials targeting: